Insider trade

Director exercised or converted 5,000 GILD derivative securities

Traded Jan 20, 2026 · Filed Jan 21, 2026

Gilead SciencesGILD

5,000
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jan 20, 2026
Reporting period: Not applicable
Filed with the SEC: Jan 21, 2026

DirectorOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001771814-26-000002

Filed / recorded

Jan 21, 2026, 9:26 PM UTC

Added to OQRO

Oct 2, 2026, 12:27 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

GILEAD SCIENCES, INC.

Issuer CIK

882095

Ticker

GILD

Reporting person

Jeffrey Bluestone

Relationship

Director

Security

Non-qualified Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

Jan 20, 2026

Transaction code

M

Shares / units

5,000

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

4,665

Ownership form

Direct

Amendment

No

Footnotes from the filing

The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting.

Around the same time

Johanna MercierChief Comm & Corp Aff Officer

Filed 8mo ago

25KShares · @ $66.64

Traded Feb 17 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

More Official record

Johanna Mercier (Chief Comm & Corp Aff Officer) sold ~$2.84M of Gilead Sciences

Scheduled in advanceFiled 8mo ago

Johanna Mercier (Chief Comm & Corp Aff Officer) sold ~$1.46M of Gilead Sciences

Scheduled in advanceFiled 8mo ago